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ASSOCIATION OF CARDIOVASCULAR BIOMARKERS WITH MYOCARDIAL 
AND CORONARY IMAGING CHARACTERISTICS IN PATIENTS HAVING 
ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS
Aim
To assess the dynamic changes and clinical significance of biomarkers of 
inflammatory processes in patients with acute myocardial infarction (MI) with/
or without type 2 diabetes mellitus (T2DM) and primary percutaneous coronary 
intervention (pPCI) at various stages of treatment. 
Methods
96 patients with acute MI after pPCI were examined. The level of inflammation 
markers was measured 4 times: before pPCI (first day from admission to the 
hospital), on the third day, 7–10 days (before discharge from the hospital) and 
40–45 days after pPCI. 
Results
All groups of patients with MI showed an increase in the plasma activity of 
biomarkers of inflammatory processes. After pPCI for 40–45 days, there is 
a significant difference in the concentration of biomarkers, depending on the 
comorbid T2DM presence. Strong associations were found between cardiovascular 
biomarkers and post-MI cardiac remodeling and coronary atherosclerosis 
progression. 
Conclusion
The assessment of the levels of biomarkers of inflammatory processes may have 
additional clinical value in estimating the course of MI, including patients with 
T2DM at the postinfarction stages.
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Background
The structural and functional rearrangement of 
the cardiovascular system during the development of 
myocardial infarction (MI) is based on disorders of 
systemic regulation of a number of pathophysiological 
processes, in particular, such as fibrosis, inflammation 
and coagulation [1, 2]. These processes have particular 
clinical severity when patients with MI have various 
comorbid disorders of carbohydrate metabolism. 
In particular, type 2 diabetes mellitus (T2DM) is 
now regarded as the equivalent of an atherosclerotic 
cardiovascular disease. MI combined with T2DM has 
less favorable clinical course with the formation of 
early and late postinfarction myocardial remodeling 
and higher rates of major adverse clinical events 
[3]. Meanwhile, elevated levels of inflammatory 
biomarkers are associated with higher cardiovascular 
risk in post-infarction patients [4, 5].
The aim of the study was to investigate serum levels 
of inflammatory biomarkers and their association












with myocardial and coronary imaging characteristics 
in patients having ST-elevation acute MI with or 
without T2DM and undergoing primary percutaneous 
coronary intervention (pPCI).
Methods
96 patients with MI were enrolled in the prospective 
study (55.4±9.8 years old, 47 male: 49 female), 50 with 
2TDM (group 1): 46 without T2DM (group 2). Serum 
levels of high sensitive C - reactive protein (hs-CRP) 
and myeloperoxidase (MPO) were serially assessed by 
quantitative immunoenzyme essays in the emergency 
department before pPCI (stage I), 24 hours after pPCI 
(stage II), 7–10 days after pPCI at discharge (stage III) 
and 40–45 days after pPCI during ambulatory follow-
up (stage IV). Echocardiography was performed on 
every stage (I–IV), Coronary Computer Tomography 
(CCT) – during one-year follow-up. Statistical 
analysis was performed in STATISTICA software 
10.0. In a case of normal distribution, the mean and 
standard deviation were calculated; when comparing 
two normally distributed samples, Student's t-test 
was used. Association between the studied indicators 
was established by Spearman rank correlation test. 
The significance level for rejecting the null statistical 
hypothesis was taken at p values less than 0.05.
Results
In MI patients with T2DM median levels of hs-CRP 
(table) and МРО were significantly higher, than in MI 
patients without T2DM on stages I–IV (p<0.01). On 
stage IV in diabetic MI patients higher median values 
of left ventricular myocardial contractility index (LV 
MCI) (1.19 vs. 1.06, p<0.05), and lower median values 
of LV ejection fraction (EF) (43% vs. 54%, p<0.05) 
transmitral E/A (0.78 vs. 0.96, p<0.05) and tissue-
doppler Em (5.8 vs. 7.2, p<0.05) were found. Also 
on stage IV correlation of hs-CRP levels with LV EF 
(r = -0.57, p<0.05), LV MCI (r = 0.53, p<0.05) and 
transmitral E/A changes (r = -0,31, p<0.05) established. 
Using linear regression we found association of CCT-
estimated new significant coronary stenoses (≥70%) at 
one-year follow-up with stage I serum levels of MPO 
(Y = 0.64, p<0.05).
Discussion
The results of this clinical study support the 
hypothesis that patients with MI and T2DM have 
a higher activity of biomarkers of the systemic 
inflammatory response, than patients with MI without 
T2DM. In the group of patients with MI and T2DM, the 
majority of unfavorable cardiovascular complications 
in the early posthospital period were recorded 
according to the data of imaging of the myocardium 
and coronary arteries (Echocardiography and CCT). 
There are clinical studies on a separate investigation of 
hs-CRP or MPO in acute MI patients [4, 5], however, 
we showed the simultaneous serum activity of both 
biomarkers in patients with MI and comorbid T2DM 
in the first one-month four-stage dynamics.
Conclusions
Hs-CRP and MPO levels assessment in MI with 
T2DM patients may be useful for early detection 
of post-infarction LV remodeling and coronary 
atherosclerotic plaques progression.
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